Josephine N Tran1, Toros Caglar2, Karen M Stockl3, Heidi C Lew4, Brian K Solow5, Paul S Chan6. 1. Senior Research Consultant, Clinical Programs and Outcomes Research, OptumRx, Irvine, CA. 2. Senior Research Consultant, Clinical Programs and Outcomes Research, OptumRx. 3. Senior Director, Clinical Programs and Outcomes Research, OptumRx. 4. Vice President, Clinical Programs, OptumRx. 5. Chief Medical Officer, Clinical, OptumRx. 6. Associate Professor, Division of Cardiology, University of Missouri-Kansas City.
Abstract
BACKGROUND: In November 2013, the American College of Cardiology (ACC) and the American Heart Association (AHA) together issued new guidelines for the treatment of patients with high cholesterol, providing a new paradigm for the management of cholesterol in the primary and secondary prevention of coronary artery disease. OBJECTIVE: To examine the impact of the 2013 ACC/AHA cholesterol treatment guidelines on pharmacy utilization of cholesterol-lowering drugs in a real-world managed care setting. METHODS: Pharmacy claims from OptumRx, a national pharmacy benefit management provider, for the period between January 1, 2013, and December 31, 2013 (baseline period), were used to identify candidates for cholesterol-lowering therapy and to estimate the number of potential patients who will be starting or intensifying statin therapy based on the updated cholesterol treatment guidelines. Potential candidates for cholesterol-lowering treatments included patients with diabetes or hypertension aged 40 to 75 years who were not already receiving a cholesterol-lowering medication, as well as patients receiving cholesterol-lowering therapies during the baseline period. The baseline cholesterol-lowering medication market share was used to project changes in pharmacy utilization over the next 3 years. RESULTS: Based on the 2013 ACC/AHA cholesterol treatment guidelines, there will be a 25% increase in the proportion of the overall population that is treated with statins over the next 3 years, increasing from 3,909,407 (27.7%) patients to 4,892,668 (34.7%) patients. The largest proportion of the increase in statin utilization is projected to be for primary prevention in patients aged 40 to 75 years who were not receiving any cholesterol-lowering treatment at baseline. These projected changes will increase the overall number of statin prescriptions by 25% and will decrease the number of nonstatin cholesterol-lowering medication prescriptions by 68% during the next 3 years. CONCLUSION: The new 2013 ACC/AHA cholesterol treatment guidelines are projected to have a significant impact on the utilization of cholesterol-lowering drugs by increasing the overall proportion of the population receiving statin therapy and by decreasing the utilization of nonstatin cholesterol-lowering medications.
BACKGROUND: In November 2013, the American College of Cardiology (ACC) and the American Heart Association (AHA) together issued new guidelines for the treatment of patients with high cholesterol, providing a new paradigm for the management of cholesterol in the primary and secondary prevention of coronary artery disease. OBJECTIVE: To examine the impact of the 2013 ACC/AHA cholesterol treatment guidelines on pharmacy utilization of cholesterol-lowering drugs in a real-world managed care setting. METHODS: Pharmacy claims from OptumRx, a national pharmacy benefit management provider, for the period between January 1, 2013, and December 31, 2013 (baseline period), were used to identify candidates for cholesterol-lowering therapy and to estimate the number of potential patients who will be starting or intensifying statin therapy based on the updated cholesterol treatment guidelines. Potential candidates for cholesterol-lowering treatments included patients with diabetes or hypertension aged 40 to 75 years who were not already receiving a cholesterol-lowering medication, as well as patients receiving cholesterol-lowering therapies during the baseline period. The baseline cholesterol-lowering medication market share was used to project changes in pharmacy utilization over the next 3 years. RESULTS: Based on the 2013 ACC/AHA cholesterol treatment guidelines, there will be a 25% increase in the proportion of the overall population that is treated with statins over the next 3 years, increasing from 3,909,407 (27.7%) patients to 4,892,668 (34.7%) patients. The largest proportion of the increase in statin utilization is projected to be for primary prevention in patients aged 40 to 75 years who were not receiving any cholesterol-lowering treatment at baseline. These projected changes will increase the overall number of statin prescriptions by 25% and will decrease the number of nonstatin cholesterol-lowering medication prescriptions by 68% during the next 3 years. CONCLUSION: The new 2013 ACC/AHA cholesterol treatment guidelines are projected to have a significant impact on the utilization of cholesterol-lowering drugs by increasing the overall proportion of the population receiving statin therapy and by decreasing the utilization of nonstatin cholesterol-lowering medications.
Authors: Andrew J Karter; Melissa M Parker; Howard H Moffet; Ameena T Ahmed; Julie A Schmittdiel; Joe V Selby Journal: Health Serv Res Date: 2009-06-03 Impact factor: 3.402
Authors: Huabing Zhang; Jorge Plutzky; Stephen Skentzos; Fritha Morrison; Perry Mar; Maria Shubina; Alexander Turchin Journal: Ann Intern Med Date: 2013-04-02 Impact factor: 25.391
Authors: Marsha A Raebel; Jennifer L Ellis; Nikki M Carroll; Elizabeth A Bayliss; Brandy McGinnis; Emily B Schroeder; Susan Shetterly; Stan Xu; John F Steiner Journal: J Gen Intern Med Date: 2011-08-31 Impact factor: 5.128
Authors: Michael J Pencina; Ann Marie Navar-Boggan; Ralph B D'Agostino; Ken Williams; Benjamin Neely; Allan D Sniderman; Eric D Peterson Journal: N Engl J Med Date: 2014-03-19 Impact factor: 91.245
Authors: Jaime Caro; Krista F Huybrechts; Wendy S Klittich; Joseph D Jackson; Alistair McGuire Journal: Am J Manag Care Date: 2003-07 Impact factor: 3.247
Authors: Qing Huang; Michael Grabner; Robert J Sanchez; Vincent J Willey; Mark J Cziraky; Swetha R Palli; Thomas P Power Journal: Am Health Drug Benefits Date: 2016-11
Authors: Dylan L Steen; Irfan Khan; Laura Becker; JoAnne M Foody; Katherine Gorcyca; Robert J Sanchez; Robert P Giugliano Journal: Clin Cardiol Date: 2016-12-27 Impact factor: 2.882
Authors: Thomas P Power; Xuehua Ke; Zhenxiang Zhao; Nicole Gidaya Bonine; Mark J Cziraky; Michael Grabner; John J Barron; Ralph Quimbo; Burkhard Vangerow; Peter P Toth Journal: Vasc Health Risk Manag Date: 2018-02-05